Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:1.16.3.1 (ceruloplasmin)
 5,074 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Certain metabolic effects were investigated in post-menopausal women undergoing oral estrogen replacement therapy for 6 months using various substances. The increases in serum concentration of the estrogen-sensitive proteins, pregnancy zone protein (PZP), and sex hormone binding globulin (SHBG) had very similar and dose-dependent patterns. Ethinyl-estradiol was found to be much more potent than the "natural" estrogens. Estriol in various doses did not increase the protein level. Gonadotropin inhibition occurred in a dose-dependent manner. In terms of FSH suppression ethinyl-estradiol was approximately 120 times as potent as the "natural" estrogens. There was a striking resemblance between the "estrogenicity" of four different estrogens when expressed both in inhibition of gonadotropins and in induction of the two serum proteins SHBG and ceruloplasmin. Estriol caused a significant depression of FSH when given orally in a dose of 2 mg three times daily. Prolactin was found to decrease during treatment with low doses of estrogens. Estrogen therapy was found to have only moderate effects on adrenal androgens. Tamoxifen, and anti-estrogen, was found to exert distinctly estrogenic effects during treatment of post-menopausal women. In post-menopausal women with low amounts of circulating estrogens the tamoxifen-receptor complex itself may produce a net estrogenic response. Serum samples from post-menopausal women treated with ethinyl estradiol 0.05 mg and estrone sulphate 2.5 mg daily were found to reduce the lymphocyte reactivity in mixed lymphocyte cultures.
 ...
PMID:Estrogen replacement therapy after the menopause. Estrogenicity and metabolic effects. 628 33

Tamoxifen is widely used as an adjuvant treatment for breast cancer. To correctly interpret laboratory test results during tamoxifen treatment, clinicians should be aware of the possible effects of the drug on laboratory tests. This study investigated the effects on serum hormones, proteins, lipids and common biochemistry in seven postmenopausal women with breast cancer during 3 months after initiating the therapy. Statistically significant decreases occurred in serum gonadotropins, alkaline phosphatase, calcium, total protein, prealbumin, orosomucoid, haptoglobin, immunoglobin M and total cholesterol whilst significant increases occurred in serum sex hormone-binding globulin (SHBG), cortisol, parathyroid hormone, aspartate aminotransferase, urate, alpha-1-antitrypsin and ceruloplasmin. The alterations could result from tamoxifen therapy, radiation or changes in lifestyle. All the changes, apart from serum urate, remained within the reference limits. In addition, only serum gonadotropins, SHBG, urate and cholesterol showed clinically significant changes. Alterations in the other laboratory tests are unlikely to disturb diagnoses based on laboratory test results during tamoxifen therapy.
 ...
PMID:Early effects of adjuvant tamoxifen therapy on serum hormones, proteins and lipids. 1081 Apr 43